《大行報告》瑞信升粵投(00270.HK)目標價至14元 評級「跑輸大市」
瑞信發表報告指,粵海投資(00270.HK)上半年純利按年升1%至27億元,分部收益及稅前盈利分別升11%及7%,大致符合該行預期,中期息升8%,略低過去年10%的升幅。
該行相信粵投派息比率會增加,目前達70%已屬中港公用股中最高之一,但整體股息增幅則有所減慢,由2017年的21%降至今年上半年的8%,以其股息率3.6%來計並不吸引,相對更穩定的香港公用股平均股息率達4.3%,以及部分中國公用股更達6.8%。
不過,基於粵投上半年較高的地產盈利表現,該行上調其2019至2021年盈利預測1%至2%,目標價相應由13.1元升至14元,但維持「跑輸大市」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.